152 results about "Slow release drug" patented technology

The invention discloses a medical developing marker and a manufacturing method thereof, and relates to the field of medical instruments, the medical developing marker comprises a closed tube, the outer wall of the closed tube is provided with a bionic barb structure, the bionic barb structure is distributed in a flexible zigzag convex manner, and the bionic barb structure and the closed tube are integrally formed through an injection molding process; a closed cavity is arranged in the closed tube, four developing strips are symmetrically arranged in the tube wall of the closed cavity, the tube wall of the region where the developing strips are located is etched to form a weak band, and a developing material layer and a sustained-release medicine layer are sequentially deposited at the weak band. The developing material layer and the sustained-release drug and / or marked nano-particle layer are alternately deposited to form a functional composite layer, and the functional composite layer can directionally rupture to release the therapeutic drug under the action of implantation pressure. The marker integrates the functions of precise development, tissue anchoring and drug sustained release, is adaptive to multi-mode imaging such as ultrasonic imaging, X-ray imaging, CT imaging, MRI imaging and PET-CT imaging, and has remarkable clinical value in precise positioning treatment of solid tumors such as breast cancer and liver cancer.

The invention relates to the technical field of pharmaceutical preparations, in particular to a solid dispersion-based sustained-release drug composite carrier as well as a preparation method and application thereof. The preparation method comprises the following steps: carrying out synergistic spray drying on double polymers (hydroxypropyl methylcellulose acetate succinate and polyvinylpyrrolidone-vinyl acetate copolymer) to form a solid dispersion; compounding with mesoporous silica and calcium silicate for localization, and spraying ethanol to activate pores; calcium stearate and magnesium stearate are sequentially added for lubrication; prefabricating a sustained-release skeleton master batch; and finally, mixing, rolling and forming. According to the method, through hierarchical structural design, the drug stability, the powder fluidity and the release controllability are remarkably improved, the method is suitable for industrial production of the dihydroergoline mesylate sustained release preparation, and a release curve is smooth and reliable.

The invention discloses bee venom-containing skin essence with small irritation and a preparation method of the bee venom-containing skin essence. The skin essence is prepared from PLGA-PEG / liposome nanoparticles, a temperature-sensitive gel matrix, a protective agent, an antioxidant, a stabilizer and ultrapure water, the preparation method comprises the following steps: preparing the PLGA-PEG / liposome nanoparticles, preparing a poloxamer 407 solution, resuspending the nanoparticles, filling and storing. According to the invention, the melittin and the snake venom-like peptide have a synergistic effect on skin wrinkle resistance, so that the skin care effect is improved; pLGA-PEG / liposome nanoparticles are matched with a poloxamer solution to construct a dual sustained-release drug system, so that the irritation of drugs to skin is reduced, the lasting effect of the drug effect is improved, and the obtained skin essence has excellent moisturizing, whitening, anti-wrinkle and antioxidant capacities and is small in irritation.

The invention provides a 4D printing esophageal stent and a preparation method thereof. The esophageal stent comprises a stent main body and a drug-loaded fiber membrane with a core-shell structure, the stent main body is a tubular stent composed of a bionic water lily hollow structure; the diameters of the head end and the tail end of the support body are larger than the diameter of the middle section, and barb structures are arranged on the outer surfaces of the head end and the tail end. The stent main body is a biodegradable shape memory polymer; the drug-loaded fibrous membrane is positioned on the outer surface of the middle section of the stent main body, and the drug-loaded fibrous membrane contains drugs. The 4D printing esophageal stent provided by the invention has excellent compressive bearing capacity and anti-slip capacity, and the drug-loaded fibrous membrane can avoid esophageal restenosis through long-term uniform slow release of drugs, so that the life safety of a patient can be further guaranteed.

The invention discloses a synthetic method of photosensitive composite hydrogel and application of the photosensitive composite hydrogel in treatment of periodontitis. The composition expression of the photosensitive composite hydrogel is MHA-B-coated Lipo, and the photosensitive composite hydrogel is prepared by the following steps: entrapping berberine hydrochloride by lipidosome with proton gradient, and then mixing with methacrylated hyaluronic acid, a photoinitiator and a cross-linking agent; according to the liposome with the proton gradient, a citric acid buffer solution is adopted for preparing blank liposome, and then alkali liquor is used for adjusting the pH value of an external phase to be alkalescent, so that the transmembrane gradient is formed. The liposome is used as a drug delivery carrier, berberine is entrapped in the liposome and is combined with the MHA hydrogel to form a composite sustained-release drug, and the composite sustained-release drug has the advantages of strong targeting property, good responsiveness, good biocompatibility and high biological safety; and the hydrogel has injectable and photosensitive cross-linking characteristics, is suitable for clinical minimally invasive operation, has the advantages of accurate immune regulation and control, and has a wide application prospect.

The invention provides a briracetam sustained-release pharmaceutical composition as well as a preparation method and application thereof. The pharmaceutical composition comprises a pharmaceutical active ingredient and a pharmaceutical excipient, wherein the pharmaceutical excipient is selected from one or more of a framework material, a disintegrating agent, a swelling agent, an adhesive, a filler and a lubricant. The briracetam sustained-release pharmaceutical composition disclosed by the invention is good in sustained-release effect, stable in release speed and small in side effect, the medicine taking frequency is reduced, and the compliance of a patient is improved; the retention time of the medicine in the stomach is prolonged, so that the medicine is continuously released in the stomach and is absorbed at the upper end of the small intestine, the effect of continuously taking effect for 24 hours is achieved, the plasma concentration is stable, and the adverse reaction is small; a patient is prevented from randomly interrupting medication, and disease relapse and malignant complication development are prevented; the medicine is few in administration times, convenient to take and small in toxic and side effects.

The invention relates to the technical field of medical materials, and particularly discloses a polyhydroxyalkanoate electrostatic spinning wound dressing as well as a preparation method and application thereof. PHA with good biocompatibility, a hydrophilic high-molecular polymer and a micromolecular drug with an anti-inflammatory effect are dissolved in an organic solvent, and the non-adhesive wound dressing with high efficiency, anti-inflammatory property and good biocompatibility is prepared through an electrostatic spinning technology. The problems that an existing wound dressing is prone to being adhered to a wound surface to cause mechanical injury and poor in biocompatibility to cause inflammation are solved, meanwhile, multiple functions such as drug sustained release, inflammation resistance, cell proliferation and angiogenesis promotion and wound surface tissue adhesion prevention are achieved, and the wound dressing has wide application prospects and considerable market value.

The invention provides a smearing sustained-release preparation and a preparation method and application thereof, the smearing sustained-release preparation comprises a chemotherapeutic drug component, an immune drug component and a sustained-release auxiliary material, and the smearing sustained-release preparation is in a transparent flowable sol shape. The sustained release preparation disclosed by the invention can be smeared and applied to a focus part in situ after a tumor operation. The application effect comprises the following steps: filling the treatment window period of the traditional postoperative adjuvant chemotherapy, and improving the local drug concentration of the focus through in-situ local slow release of the drug, thereby effectively removing residual tumor tissues and reducing the systemic toxicity of drug treatment; the metastasis and recurrence rate of tumors are further inhibited through the synergistic combined effect of chemotherapy-immune drugs in the preparation. The advantages show that the smearing sustained-release preparation provided by the invention has huge clinical potential in the aspect of tumor treatment.

The invention provides a sustained-release drug stent for tracheal lesion tissues and a preparation method thereof, and belongs to the technical field of medical instruments. The stent takes a nickel-titanium alloy wire as a base material, after acid pickling, weaving and heat treatment shaping, a drug coating is loaded through multiple steps: firstly, an anti-tumor or anti-inflammatory drug is mixed with a PLGA solution to form nano-particles; then, carrying out chitosan modification and dopamine coating, so as to obtain PLGA-PDA drug carrier nanoparticles; then, nano-particles are sprayed on the surface of the stent to form a drug coating; and finally, coating a PLGA-HA composite solution to enhance the performance of the stent. By optimizing the material and the coating structure, accurate slow release of the medicine is achieved, relapse and restenosis of tracheal lesion tissue are effectively inhibited, the treatment effect and safety are improved, and a new scheme is provided for tracheal lesion treatment.

The invention relates to a sustained-release pharmaceutical preparation of a fused tricyclic gamma-amino acid derivative and a preparation method of the sustained-release pharmaceutical preparation. The fused tricyclic gamma-amino acid derivative is a compound as shown in a formula (I) or a stereoisomer, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a co-crystal thereof.

This application relates to the field of pharmaceutical equipment technology, and discloses an apparatus and method for granulating sustained-release drugs, to solve the problem of rapid drug release from sustained-release tablets due to short compression time and lack of compaction. A granulation structure is fixedly installed inside a housing. The granulation structure includes a fixed plate, a support shaft, a rotating gear, and a granulation belt. The granulation belt has a granulation groove, and two granulation belts are installed in a V-shape. Powdered sustained-release drug is discharged into the granulation groove. A power motor drives the support shaft, rotating gear, and granulation belt to rotate in opposite directions, causing the granulation groove to compress the powdered sustained-release drug in the granulation groove. As the granulation groove moves from the top to the bottom of the granulation belt, the compressive force on the powdered sustained-release drug increases, and the compression time of the powdered sustained-release drug in the granulation groove is extended, so that the powdered sustained-release drug is compacted, preventing breakage of the compressed sustained-release tablets.

The invention provides metal organic framework-cellulose composite aerogel as well as a preparation method and application thereof, and belongs to the technical field of perfume slow release. According to the method, Northern bleached softwood kraft pulp (NBSK) is taken as a cellulose source, and nanocellulose (NCNF) is prepared through TEMPO-mediated oxidation reaction, so that the dispersity and reaction activity of cellulose can be improved; nCNF and MOF materials are compounded, and the aerogel material with a high specific surface area and a hierarchical pore structure is prepared through freeze drying. The prepared metal organic framework-cellulose composite aerogel has excellent mechanical performance and adsorption performance, and can effectively solve the problems of volume shrinkage, low adsorption capacity, non-uniform release, insufficient mechanical performance and the like of a traditional aerogel material in the perfume adsorption process. The material has wide application prospects in the fields of cigarette flavor adsorption and slow release, drug delivery, environment purification and the like.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a composition containing a Nicodil multi-tablet structure and capable of realizing stepped slow controlled-release drug delivery. The invention relates to a composition containing a Nicodil multi-tablet structure stepped slow controlled-release drug delivery. The composition comprises a capsule shell and at least two micro-structure drug-containing bodies with different release rates, wherein the capsule shell is filled with the micro-structure drug-containing bodies; the microstructure drug-containing body is selected from at least two of a sustained-release tablet, an enteric-coated tablet and a quick-release tablet; and the microstructure drug-containing body contains an active drug Nicodil. The composition disclosed by the invention realizes rapid and stable slow-release drug release, overcomes side effects caused by a plasma ultra-safe interval due to burst release, ensures that a plasma treatment concentration is rapidly reached, realizes slow release, remarkably reduces degradation of active components in the composition, and improves the stability of the composition.

The application discloses a sustained-release LBQ657 hydrogel capable of treating fibrosis and a preparation method thereof, and belongs to the technical field of material synthesis and biological medicine. The sustained-release LBQ657 hydrogel comprises chitosan, beta-glycerophosphoric acid sodium, distilled water and LBQ657. The w / v concentration of the chitosan solution used for configuration of the hydrogel is 3.3%, the w / v concentration of the beta-glycerophosphoric acid sodium aqueous solution is 56%, and the volume ratio of the chitosan solution to the beta-glycerophosphoric acid sodium solution is 4:1-10:1. The sustained-release LBQ657 hydrogel can quickly form a stable gel and is well adhered to the esophagus after being covered on the surface of the esophagus, can provide a protection for at least 7 days under physiological conditions, can significantly relieve TGF-beta induced fibrosis, and can provide a new idea for esophageal fibrosis treatment by covering the wound and long-term drug release.

The present application relates to the technical field of HPV repair, in particular to a long-acting sustained-release device combination for treating female vaginal HPV infection and a use method thereof, which provides a safe, low-irritation and convenient-to-use drug delivery mode, and comprises a vaginal drug delivery device A and a device B used in cooperation with each other, the magnetic therapy of the vaginal drug delivery device A can promote capillary dilation and improve microcirculation, the IgY in the drug sustained-release layer of the vaginal drug delivery device A can be stably kept in the gel at a high titer, the alginate sulfate-carboxymethyl chitosan composite microemulsion makes the drug more easily gathered at the infection site, the magnetic therapy and the sustained-release drug interact with each other, promote the absorption and dissipation of inflammation, and produce a good repair environment, the functional powder dressing of the subsequent vaginal drug delivery device B is convenient for mild absorption of the exudate on the surface of the vagina after the magnetic therapy and the drug sustained-release treatment without causing discomfort, and the functional powder dressing releases various ions at a certain rate, further repairing damaged cells and tissues.

The present disclosure relates to a drug delivery system comprising an intraocular pressure-lowering agent, a neurotrophic agent such as a CNTF compound, a C-type natriuretic peptide (CNP) compound, a Tie-2 agonist, a natriuretic peptide receptor B (NPR-B) compound, or an apoptosis signaling fragmentation inhibitor (FAS) or FAS ligand (FASL) inhibitor (including any combination of these compounds), and a sustained-delivery component. Methods, medicaments, kits, methods of use, and methods of manufacture for treating glaucoma or related conditions are also disclosed. [Selection diagram] None

The utility model provides an ophthalmic sustained-release medicine injector, which comprises a shell, an ejection button, a needle tube and a pushing mechanism, and is characterized in that the shell forms a handle part of the injector; the ejection button is partially exposed out of the shell and can trigger the pushing mechanism to longitudinally move in the shell, the needle tube is fixed to the head end of the handle part, and slow-release medicine can be contained in the needle tube; when the injector is in a pre-ejection state, the pushing mechanism is stopped at the ejection button; in the ejection state, an operator triggers the ejection button so that the pushing mechanism can longitudinally move in the shell, the bonding force between the sustained-release medicine and the needle tube is overcome, and the sustained-release medicine in the needle tube is smoothly ejected out and delivered into the eye. The injection device is simple in overall structure and convenient to use, the sustained-release medicine implantation process is fast, and the learning curve of an operator is short.

The invention provides a microsphere composition for a contraceptive microneedle and the contraceptive microneedle containing the composition. The microsphere composition for the contraceptive microneedle comprises one selected from the group consisting of sustained-release estrogen microspheres, sustained-release progesterone microspheres and mixtures thereof, and the sustained-release estrogen microspheres comprise 400-600 parts by weight of biodegradable polymer per 100 parts by weight of estrogen, every 100 parts by weight of progesterone and hydroxypropyl-beta-cyclodextrin (HP [beta] CD) in the sustained-release progesterone microspheres comprise 700-900 parts by weight of a biodegradable polymer, and the molar ratio of the progesterone to the hydroxypropyl-beta-cyclodextrin is (1: 2)-(1: 3). The microsphere composition for a contraceptive microneedle according to the present invention can stably encapsulate a drug, exhibits a sustained-release drug effect for at least one week, and has a particle size (Dv90) suitable for a microneedle. According to the contraceptive microneedle or the contraceptive microneedle patch, administration is convenient, the contraceptive microneedle or the contraceptive microneedle patch is used once a week, the transdermal medicine permeability is good, the short attachment time is allowed, and the medicine is slowly released for at least one week.

The application provides an immersion solution for a corneal contact lens, a preparation method and the corneal contact lens, and the immersion solution is prepared from the following raw materials in mass percentage: letastigmine 0.01-0.15%; buffer salt 0.1-2%; sodium chloride 0.2-1.2%; sodium thiosulfate 0-0.5%; and pure water 97-99%. The immersion solution for the corneal contact lens prepared by the application can well interact with water molecules in the corneal contact lens, so that the drug molecules in the immersion solution are well replaced in the corneal contact lens, the drug molecules are retained in the gel network of the corneal contact lens, high drug loading is achieved, the bioavailability of the drug is improved, the corneal contact lens prepared by the immersion solution has a drug slow-release effect, directly acts on the eyes and can reduce the toxic and side effects of the drug.

The invention relates to the technical field of drugs for treating alopecia, in particular to sustained-release drug microparticles for treating alopecia, a preparation method of the sustained-release drug microparticles and a sustained-release injection, and the sustained-release drug microparticles for treating alopecia are prepared from, by weight, 3-10 parts of degradable polymer, 1-5 parts of drugs for treating alopecia, 0.5-5 parts of emulsifier, 0.3-3 parts of antibacterial agent and 77-95.2 parts of water. The problem that the solubility of the medicine in water is poor is effectively solved, and convenient conditions are provided for development of a novel administration mode; the sustained-release drug microparticles for treating alopecia avoid the use of volatile solvents such as ethanol and ethylene glycol, and the drug can be directly dispersed in water, so that skin dryness and anaphylaxis (such as alopecia, dandruff and the like) are not easy to cause; according to the sustained-release drug microparticle for treating alopecia, the drug release mode is sustained release, the administration frequency is effectively reduced, and the application mode is distinguished (3-4 times or even more times are possibly needed in a week), so that the sustained-release drug microparticle for treating alopecia only needs to be injected 1-2 times per month.

The invention discloses a preparation method of a non-Newtonian fluid-based temperature-shear dual response type ophthalmic sustained-release drug carrier, and belongs to the technical field of ophthalmic medicines. The preparation is composed of a dispersed phase (a temperature response type targeting nano-drug carrier) and a continuous phase (a non-Newtonian fluid matrix), wherein the mass fraction of the dispersed phase in the continuous phase is 0.5-2%. The temperature response type targeted nano-drug carrier is of a core-shell two-layer structure, the core is composed of a PLGA-PEG copolymer and an active drug, the shell is formed by grafting poly N-isopropylacrylamide (PNIPAM) and hyaluronic acid, and the lowest critical solution temperature (LCST) of the PNIPAM is 35-37 DEG C; the non-Newtonian fluid matrix is a pseudoplastic fluid, is composed of Carbomer 940 and triethanolamine, and has a shear thinning characteristic. The preparation method comprises the following three steps: preparation of the temperature response type targeting nano-drug carrier, preparation of the non-Newtonian fluid matrix and low-speed dispersion and compounding of the two. According to the invention, shear-response convenient administration, temperature-response precise drug release and long-acting retention synergism are realized, the bioavailability of the drug and the compliance of a patient are remarkably improved, the stability is excellent, the preparation process is simple and controllable, and the preparation method is suitable for long-acting targeted therapy of chronic eye diseases such as allergic conjunctivitis, chronic xerophthalmia, glaucoma and the like.

The invention provides a uterine cavity treatment device, and belongs to the technical field of uterine cavity postoperative continuous treatment devices. The treatment device comprises a uterine cavity support and a conveying system, the uterine cavity support comprises a supporting framework and a medicine carrying covering film, a main body of the supporting framework is of a big-end-up three-dimensional cage-shaped structure, angle-shaped protrusions are symmetrically arranged on the left side and the right side of the far end of the supporting framework, and the angle-shaped protrusions obliquely extend upwards with the center of the uterine cavity support as the reference; an arc-shaped structure is formed, so that the whole shape of the supporting skeleton is matched with the uterus shape after the supporting skeleton is automatically expanded; the medicine carrying covering film is at least arranged on the outer side of the supporting framework; a hormone sustained-release drug is arranged in the drug-loading covering membrane and is used for promoting repair of endometrium; the conveying system is used for loading the uterine cavity stent in a contracted state and conveying the uterine cavity stent to a target position to complete release; the technical problem that in the prior art, the effect of treating intrauterine adhesion after an intrauterine operation is poor is mainly solved.

Provided are methods and compositions for cell-based drug screening with high-density arrays of conical microwells and slow-drug-release beads.

This invention proposes an embolic microsphere capable of sustained drug release and controlled degradation rate, and its preparation method. The method includes: dissolving a dispersant in an oil phase liquid and stirring at a first preset temperature to obtain a dispersion; dissolving gelatin in water at a second preset temperature to obtain a gelatin solution; dissolving a compound with negatively charged groups in water, adding an alkali solution and an initiator under ice bath conditions to obtain a modified solution; adding the modified solution to the gelatin solution and stirring to obtain an aqueous prepolymer solution, which is then added dropwise to the dispersion for premixing; adding a crosslinking agent and a catalyst; and directly grafting the negatively charged groups onto the gelatin molecules via low-temperature free radical polymerization to obtain an intermediate product; and then performing post-treatment to obtain embolic microspheres. This invention eliminates the need for non-degradable materials, enabling the direct grafting of negatively charged groups onto the gelatin surface, resulting in embolic microspheres with highly efficient drug loading capacity, excellent long-term sustained drug release, and controlled degradation rate.

The invention relates to the technical field of medical auxiliary devices, and discloses a stoma pocket which comprises a base plate and a collecting bag, the base plate is provided with a bonding layer used for being attached to the periphery of a stoma, and the collecting bag is detachably connected with the base plate and used for collecting stoma discharge. The device is characterized in that the collecting bag comprises a collecting area located on the lower portion and a drug delivery area located at the stoma, a transparent observation window is arranged at the position, corresponding to the stoma, of the drug delivery area, a layer of sustained-release drug carrier is attached to the drug delivery area of the collecting bag, a porous hydrophobic membrane is attached to the surface of the sustained-release drug carrier, the sustained-release drug carrier carries sustained-release drugs, and the hydrophobic membrane is attached to the surface of the sustained-release drug carrier. The sustained-release drug comprises composite microspheres carrying polylactic acid / polycaprolactone, the drug is wrapped in the microspheres, and the problem of stoma infection caused by frequent opening of a stoma bag during drug administration is solved by performing sustained drug release on the stoma.

To provide a solid preparation of a sustained-release pharmaceutical composition in which even a solid preparation has excellent structural stability while maintaining an effect of sustained-release of a pharmaceutical composition.SOLUTION: A solid preparation of a sustained-release pharmaceutical composition contains: (1) (R)-2-(2-aminothiazole-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl] acetic acid anilide or a pharmaceutically acceptable salt thereof; (2) one or more kinds of polymeric substances which form hydrogel having the average molecular weight of 100,000 or more or in which 5% aqueous solution has viscosity of 25°C 12 mPa s or more; and (3) one or more kinds of non-hydrophilic additives showing dissolubility that [amount of water for dissolving 1 g at 20±5°C exceeds 10 mL], where the solid preparation without considering coating does not contain a hydrophilic component showing dissolubility that [amount of water for dissolving 1 g at 20±5°C is 10 mL or less] other than a polymeric substance forming hydrogel of the component (2).SELECTED DRAWING: Figure 2

The present invention relates to a sustained-release pharmaceutical composition using a GLP-1 receptor agonist. Specifically, microparticles comprising semaglutide are prepared using a 5-hydroxydopamine-modified self-crosslinkable hyaluronic acid derivative (SAMH) as a carrier, and the semaglutide is gradually released over a long period of time upon injection into the body, thereby providing excellent effects on blood glucose control and weight management. The sustained-release pharmaceutical composition according to the present invention maintains a low viscosity before administration to the human body, thus being easily administered by injection, and is self-crosslinked and hydrogelated after administration to the human body, and thus can maintain the pharmacological effect of the semaglutide for a long period of time with only a single administration.

The invention discloses a compound preparation entrapped with a QC inhibitor as well as a preparation method and application of the compound preparation, and relates to the technical field of medicinal chemistry and biological materials. The composite preparation comprises a drug-loaded micelle and a hydrogel loaded with the drug-loaded micelle, the drug-loaded micelle comprises a QC inhibitor or a prodrug thereof, and a polyethylene glycol-polyamino acid block copolymer and a nonionic surfactant which entrap the QC inhibitor or the prodrug thereof, the structural formula of the QC inhibitor is shown in the specification. The hydrogel is prepared from chitosan, beta-sodium glycerophosphate and water. According to the compound preparation, a double sustained-release system of'hydrogel macroscopic sustained-release drug-loaded micelle and drug-loaded micelle microcosmic sustained-release drug 'is constructed, the release rate of a QC inhibitor is greatly delayed, the effective blood concentration can be maintained for several weeks, the administration interval is expected to be prolonged, and the compliance of a patient is remarkably improved.

The present invention belongs to the technical field of medical devices, and particularly relates to an embolic microsphere with an interpenetrating polymer network structure and a preparation method thereof. The embolic microsphere is formed by the entanglement and interpenetration of molecular chains between a polyvinyl alcohol polymer network formed by the free radical polymerization cross-linking of modified polyvinyl alcohol molecules and a polyamino acid network formed by the reaction of polyamino acids with a carbodiimide cross-linking agent and a cross-linking monomer to form a three-dimensional mechanical interlocking structure; wherein, the polyvinyl alcohol polymer network and the polyamino acid network do not form a chemical bond. In the present invention, an interlocking structure is formed by cross-linking polyvinyl alcohol and a degradable polyamino acid. Polyvinyl alcohol serves as an elastic skeleton, having good elasticity and recoverability, reducing the risk of fragmentation during delivery. After the degradable polymer degrades, the polyvinyl alcohol skeleton still plays an embolic role, reducing the risk of vascular recanalization. At the same time, the polyamino acid network has active functional groups, which can degrade and slowly release drugs.